The HPV testing & PAP test market is expected to register a CAGR of 6.50%, during the forecast period, with a revenue of approximately USD 3550 million in 2020 and expected to reach USD 5180 million by 2026. The driving factors of the market are the increasing number of cervical cancer cases across the globe, an increasing number of cervical cancer screening programs, and the introduction of advanced technologies.
In 2020, with the rising COVID-19 pandemic globally, various elective medical procedures, including cancer screening, were found to be largely put on hold to prioritize the other urgent needs and reduce the risk of the spread of COVID-19. This has shown a substantial decline in cancer screening. Therefore as the health systems will the primary care appointments will reopen and will resume preventive care visits.
According to the World Health Organization, among women, cervical cancer is the fourth most common cancer, with an estimated 570,000 new cases in 2018, representing 6.6% of all female cancers. Approximately, 90% of deaths from cervical cancer occur in middle- to low-income countries.
Additionally, according to the American Cancer Society estimates about 13,170 new cases of invasive cervical cancer were diagnosed and about 4,250 women died from cervical cancer in the United States in the year 2019. Additionally, according to Cancer Australia, the number of new cases of cervical cancer diagnosed in 2019 were found to be 951 females. Thus, globally, the increasing number of cervical cancer cases may increase the demand for HPV testing andPAP tests that help in the growth of the market.
The growing number of cervical cancer cases increases the demand for screening programs. The tests are found to address deficiencies in traditional cervical screening that has led to alternative screening paradigms such as those involving detection of the human papillomavirus (HPV). Companies like Qiagen NV are having technologically advanced tests that detect HPV DNA such as Capture 2 test which detects the presence of 13 high-risk HPV types in the cervical sample. Hence all these factors has impacted the overall market growth.
Key Market Trends
Cervical Cancer Screening Test is Expected to be the Dominant Over the Forecast Period
Cervical cancer screening is found to play and an essential part of a woman's routine health care. For women with the age of 30 and above, an HPV test is being recommended for detection. The screening helps to identify precancerous lesions caused by HPV so they can be removed to prevent invasive cancers from developing.
With the rising COVID-19 burden, cervical cancer procedures and screening were found to be paused in 2020 and only the urgent procedures were being performed that has impacted the overall market growth. The cancer diagnosis was found to be delayed as screening and diagnostic services were reduced or suspended in many countries, but post-pandemic the situation is expected to be better with the services being resumed which will show positive growth.
The major factor driving the growth of the segment include the rising burden of cervical cancer across the world. The disease is more commonly found in females. According to the World Health Organization, there are more than 270,000 women die every year due to cervical cancer.
According to the American Society of Clinical Oncology, in 2019 it was estimated that about 13,170 women in the United States will be diagnosed with invasive cervical cancer. The incidence rates for the disease dropped by more than 50% between 1975 and 2015 due in part to an increase in screening, Therefore the cervical cancer are found to increase every year. In most cases, cervical cancer can be prevented through early detection and treatment of abnormal cell changes that occur in the cervix years before cervical cancer develops. Therefore with the increasing adoption of early diagnosis, the market is expected to grow positively during the forecasted period.
The cervical cancer screening tests segment is thus found dominating the segment owing to the increasing awareness about the benefits associated with the early detection of cancer and the rising government support towards controlling the cervical cancer. Hence all these factors are expected to drive the market growth.
North America Region Expected to Dominate the Market of HPV Testing & PAP Test Over the Forecast Period
The market in the North America region has been found dominating due to the increased number of cervical cancer cases and the growing number of screening procedures.
With the rising COVID-19 burden, HPV testing and PAP testing were found to be paused that have majorly impacted the overall market growth. There has been a dramatic impact on cervical cancer screening, which decreased by 90% as compared to the previous years. As health systems will re-open primary care appointments and resume preventive care visits, will slowly increase the clinic-based cervical cancer screening procedures.
Cervical cancer is found to be one of the most common causes of deaths among women in the United States. According to the American Cancer Society, in 2020, there are around 13,800 new cases of invasive cervical cancer that were being diagnosed and about 4,290 women died from cervical cancer. The death rate due to cervical cancer has observed to have dropped over the last 40 years, by up to more than 50%, with the increased use of testing.
Thus there is no FDA-approved HPV test for men currently but there are only approved tests to find HPV in a woman's cervix and the hence the rising number of cervical cancer cases has boosted the demand for diagnostic HPV testing and Pap testing market.
There is one HPV test that has recently been approved (Cobas test) for use as primary cervical cancer screening for women age 25 and older, followed by a Pap test for women with certain results.) There are also many new tests in development that can improve the evaluation of HPV-positive women. Thus, due to the increasing demand for pap, HPV, and other tests for cancer screening, the market is expected to increase.
Additionally, favorable government policies in North America are expected to drive the overall market during the forecast period. In the United States, the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) for breast and cervical cancer screening has helped in driving the overall market growth.
Some of the major players in the HPV test and Pap test market include: Abbott Laboratories, Qiagen, Becton, Dickinson and Company, F. Hoffmann-La Roche Ltd, and many others. These key players are found focussing on inorganic and organic strategies such as product approvals & licenses, agreements, collaborations, and partnerships, expansions, acquisitions to sustain their growth in the HPV testing and Pap test market. Also, receiving approvals from regulatory authorities for new product launches will render the company with a competitive advantage.
Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
TABLE OF CONTENTS
- 1.1 Study Deliverables
- 1.2 Study Assumptions
- 1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
- 4.1 Market Overview
- 4.2 Market Drivers
- 4.2.1 Increasing Number of Cervical Cancer Cases
- 4.2.2 Increasing Number of Cervical Cancer Screening Programs
- 4.2.3 Introduction to Advanced Technologies
- 4.3 Market Restraints
- 4.3.1 HPV Vaccination
- 4.3.2 Changes in Regulatory Guidelines for Cervical Cancer Screening
- 4.4 Porter's Five Force Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
- 5.1 By Test Type
- 5.1.1 HPV Test
- 5.1.2 PAP Test
- 5.1.3 Co-Testing
- 5.2 By Application
- 5.2.1 Cervical Cancer Screening Test
- 5.2.2 Head and Neck Cancer Screening Test
- 5.2.3 Other Applications
- 5.3 By End User
- 5.3.1 Hospitals/Clinics
- 5.3.2 Diagnostic Centers
- 5.3.3 Point-of-Care/Self-sampling
- 5.4 Geography
- 5.4.1 North America
- 22.214.171.124 United States
- 126.96.36.199 Canada
- 188.8.131.52 Mexico
- 5.4.2 Europe
- 184.108.40.206 Germany
- 220.127.116.11 United Kingdom
- 18.104.22.168 France
- 22.214.171.124 Italy
- 126.96.36.199 Spain
- 188.8.131.52 Rest of Europe
- 5.4.3 Asia-Pacific
- 184.108.40.206 China
- 220.127.116.11 Japan
- 18.104.22.168 India
- 22.214.171.124 Australia
- 126.96.36.199 South Korea
- 188.8.131.52 Rest of Asia-Pacific
- 5.4.4 Middle East and Africa
- 184.108.40.206 GCC
- 220.127.116.11 South Africa
- 18.104.22.168 Rest of Middle East and Africa
- 5.4.5 South America
- 22.214.171.124 Brazil
- 126.96.36.199 Argentina
- 188.8.131.52 Rest of South America
6 COMPETITIVE LANDSCAPE
- 6.1 Company Profiles
- 6.1.1 Arbor Vita Corporation
- 6.1.2 Danaher Corporation (Cepheid)
- 6.1.3 Seegene Inc.
- 6.1.4 Becton, Dickinson and Company
- 6.1.5 TruScreen
- 6.1.6 Abbott Laboratories
- 6.1.7 Hologic, Inc.
- 6.1.8 Qiagen NV
- 6.1.9 F. Hoffmann-La Roche AG
- 6.1.10 Quest Diagnostics
- 6.1.11 OncoHealth Corporation
- 6.1.12 Netdox Health Pvt. Ltd.
- 6.1.13 Femasys Inc.,
- 6.1.14 Cepheid Inc.
- 6.1.15 Takara Bio Inc.
- 6.1.16 DiagCor Bioscience Inc Ltd
- 6.1.17 Fujirebio Diagnostics, Inc.
- 6.1.18 Zytovision GmbH
- 6.1.19 Medical & Biological Laboratories Co., Ltd
- 6.1.20 Promega Corporation
7 MARKET OPPORTUNITIES AND FUTURE TRENDS